PubMed:11926891 JSONTXT

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"11926891-0#0#11#gene6696","span":{"begin":370,"end":456},"obj":"gene6696"},{"id":"11926891-0#52#66#diseaseC0029925","span":{"begin":1629,"end":1749},"obj":"diseaseC0029925"},{"id":"11926891-0#52#66#diseaseC1140680","span":{"begin":1629,"end":1749},"obj":"diseaseC1140680"},{"id":"11926891-10#0#11#gene6696","span":{"begin":2289,"end":2300},"obj":"gene6696"},{"id":"11926891-10#84#109#diseaseC0677886","span":{"begin":2373,"end":2398},"obj":"diseaseC0677886"},{"id":"11926891-10#207#222#diseaseC0029928","span":{"begin":2496,"end":2511},"obj":"diseaseC0029928"},{"id":"11926891-8#39#50#gene6696","span":{"begin":1810,"end":1821},"obj":"gene6696"},{"id":"11926891-8#163#176#diseaseC0919267","span":{"begin":1934,"end":1947},"obj":"diseaseC0919267"},{"id":"11926891-9#22#33#gene6696","span":{"begin":1995,"end":2006},"obj":"gene6696"},{"id":"11926891-9#181#192#gene6696","span":{"begin":2154,"end":2165},"obj":"gene6696"},{"id":"11926891-9#128#153#diseaseC0862506","span":{"begin":2101,"end":2126},"obj":"diseaseC0862506"}],"relations":[{"id":"0#11#gene669652#66#diseaseC0029925","pred":"associated_with","subj":"11926891-0#0#11#gene6696","obj":"11926891-0#52#66#diseaseC0029925"},{"id":"0#11#gene669652#66#diseaseC1140680","pred":"associated_with","subj":"11926891-0#0#11#gene6696","obj":"11926891-0#52#66#diseaseC1140680"},{"id":"0#11#gene669684#109#diseaseC0677886","pred":"associated_with","subj":"11926891-10#0#11#gene6696","obj":"11926891-10#84#109#diseaseC0677886"},{"id":"0#11#gene6696207#222#diseaseC0029928","pred":"associated_with","subj":"11926891-10#0#11#gene6696","obj":"11926891-10#207#222#diseaseC0029928"},{"id":"39#50#gene6696163#176#diseaseC0919267","pred":"associated_with","subj":"11926891-8#39#50#gene6696","obj":"11926891-8#163#176#diseaseC0919267"},{"id":"22#33#gene6696128#153#diseaseC0862506","pred":"associated_with","subj":"11926891-9#22#33#gene6696","obj":"11926891-9#128#153#diseaseC0862506"},{"id":"181#192#gene6696128#153#diseaseC0862506","pred":"associated_with","subj":"11926891-9#181#192#gene6696","obj":"11926891-9#128#153#diseaseC0862506"}],"text":"Osteopontin as a potential diagnostic biomarker for ovarian cancer.\nCONTEXT: Development of new biomarkers for ovarian cancer is needed for early detection and disease monitoring. Analyses involving complementary DNA (cDNA) microarray data can be used to identify up-regulated genes in cancer cells, whose products may then be further validated as potential biomarkers.\nOBJECTIVE: To describe validation studies of an up-regulated gene known as osteopontin, previously identified using a cDNA microarray system.\nDESIGN, SETTING, AND PARTICIPANTS: Experimental and cross-sectional studies were conducted involving ovarian cancer and healthy human ovarian surface epithelial cell lines and cultures, archival paraffin-embedded ovarian tissue collected between June 1992 and June 2001, and fresh tissue and preoperative plasma from 144 patients evaluated for a pelvic mass between June 1992 and June 2001 in gynecologic oncology services at 2 US academic institutions. Plasma samples from 107 women selected from an epidemiologic study of ovarian cancer initiated between May 1992 and March 1997 were used as healthy controls.\nMAIN OUTCOME MEASURES: Relative messenger RNA expression in cancer cells and fresh ovarian tissue, measured by real-time polymerase chain reaction as 2(-DeltaDeltaCT)(a quantitative value representing the amount of osteopontin expression); osteopontin production, localized and scored in ovarian healthy and tumor tissue with immunohistochemical studies; and amount of osteopontin in patient vs control plasma, measured using an enzyme-linked immunoassay.\nRESULTS: The geometric mean for 2(-DeltaDeltaCT)for osteopontin expression in 5 healthy ovarian epithelial cell cultures was 4.1 compared with 270.4 in 14 ovarian cancer cell lines (P =.03). The geometric mean 2(-DeltaDeltaCT)for osteopontin expression in tissue from 2 healthy ovarian epithelial samples was 9.0 compared with 164.0 in 27 microdissected ovarian tumor tissue samples (P =.06). Immunolocalization of osteopontin showed that tissue samples from 61 patients with invasive ovarian cancer and 29 patients with borderline ovarian tumors expressed higher levels of osteopontin than tissue samples from 6 patients with benign tumors and samples of healthy ovarian epithelium from 3 patients (P =.03). Osteopontin levels in plasma were significantly higher (P\u003c.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).\nCONCLUSIONS: Our findings provide evidence for an association between levels of a biomarker, osteopontin, and ovarian cancer and suggest that future research assessing its clinical usefulness would be worthwhile."}

{"project":"CoMAGC","denotations":[{"id":"T1","span":{"begin":2289,"end":2300},"obj":"Gene"},{"id":"E1","span":{"begin":2301,"end":2307},"obj":"Gene_expression"},{"id":"E2","span":{"begin":2337,"end":2343},"obj":"Positive_regulation"},{"id":"T2","span":{"begin":2373,"end":2398},"obj":"ovarian cancer"},{"id":"T3","span":{"begin":2384,"end":2398},"obj":"ovarian cancer"}],"relations":[{"id":"R1","pred":"themeOf","subj":"T1","obj":"E1"},{"id":"R2","pred":"themeOf","subj":"E1","obj":"E2"},{"id":"R3","pred":"CGE-increased","subj":"T1","obj":"T2"},{"id":"R4","pred":"CCS-normalTOcancer","subj":"T1","obj":"T2"},{"id":"R5","pred":"PT-observation","subj":"T1","obj":"T2"},{"id":"R3","pred":"IGE-unchanged","subj":"T1","obj":"T2"}],"text":"Osteopontin as a potential diagnostic biomarker for ovarian cancer.\nCONTEXT: Development of new biomarkers for ovarian cancer is needed for early detection and disease monitoring. Analyses involving complementary DNA (cDNA) microarray data can be used to identify up-regulated genes in cancer cells, whose products may then be further validated as potential biomarkers.\nOBJECTIVE: To describe validation studies of an up-regulated gene known as osteopontin, previously identified using a cDNA microarray system.\nDESIGN, SETTING, AND PARTICIPANTS: Experimental and cross-sectional studies were conducted involving ovarian cancer and healthy human ovarian surface epithelial cell lines and cultures, archival paraffin-embedded ovarian tissue collected between June 1992 and June 2001, and fresh tissue and preoperative plasma from 144 patients evaluated for a pelvic mass between June 1992 and June 2001 in gynecologic oncology services at 2 US academic institutions. Plasma samples from 107 women selected from an epidemiologic study of ovarian cancer initiated between May 1992 and March 1997 were used as healthy controls.\nMAIN OUTCOME MEASURES: Relative messenger RNA expression in cancer cells and fresh ovarian tissue, measured by real-time polymerase chain reaction as 2(-DeltaDeltaCT)(a quantitative value representing the amount of osteopontin expression); osteopontin production, localized and scored in ovarian healthy and tumor tissue with immunohistochemical studies; and amount of osteopontin in patient vs control plasma, measured using an enzyme-linked immunoassay.\nRESULTS: The geometric mean for 2(-DeltaDeltaCT)for osteopontin expression in 5 healthy ovarian epithelial cell cultures was 4.1 compared with 270.4 in 14 ovarian cancer cell lines (P =.03). The geometric mean 2(-DeltaDeltaCT)for osteopontin expression in tissue from 2 healthy ovarian epithelial samples was 9.0 compared with 164.0 in 27 microdissected ovarian tumor tissue samples (P =.06). Immunolocalization of osteopontin showed that tissue samples from 61 patients with invasive ovarian cancer and 29 patients with borderline ovarian tumors expressed higher levels of osteopontin than tissue samples from 6 patients with benign tumors and samples of healthy ovarian epithelium from 3 patients (P =.03). Osteopontin levels in plasma were significantly higher (P\u003c.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).\nCONCLUSIONS: Our findings provide evidence for an association between levels of a biomarker, osteopontin, and ovarian cancer and suggest that future research assessing its clinical usefulness would be worthwhile."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":2289,"end":2300},"obj":"gene:6696"},{"id":"T1","span":{"begin":2373,"end":2398},"obj":"disease:C0677886"},{"id":"T2","span":{"begin":2289,"end":2300},"obj":"gene:6696"},{"id":"T3","span":{"begin":2496,"end":2511},"obj":"disease:C0029928"},{"id":"T4","span":{"begin":2289,"end":2300},"obj":"gene:6696"},{"id":"T5","span":{"begin":2566,"end":2573},"obj":"disease:C0006826"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Osteopontin as a potential diagnostic biomarker for ovarian cancer.\nCONTEXT: Development of new biomarkers for ovarian cancer is needed for early detection and disease monitoring. Analyses involving complementary DNA (cDNA) microarray data can be used to identify up-regulated genes in cancer cells, whose products may then be further validated as potential biomarkers.\nOBJECTIVE: To describe validation studies of an up-regulated gene known as osteopontin, previously identified using a cDNA microarray system.\nDESIGN, SETTING, AND PARTICIPANTS: Experimental and cross-sectional studies were conducted involving ovarian cancer and healthy human ovarian surface epithelial cell lines and cultures, archival paraffin-embedded ovarian tissue collected between June 1992 and June 2001, and fresh tissue and preoperative plasma from 144 patients evaluated for a pelvic mass between June 1992 and June 2001 in gynecologic oncology services at 2 US academic institutions. Plasma samples from 107 women selected from an epidemiologic study of ovarian cancer initiated between May 1992 and March 1997 were used as healthy controls.\nMAIN OUTCOME MEASURES: Relative messenger RNA expression in cancer cells and fresh ovarian tissue, measured by real-time polymerase chain reaction as 2(-DeltaDeltaCT)(a quantitative value representing the amount of osteopontin expression); osteopontin production, localized and scored in ovarian healthy and tumor tissue with immunohistochemical studies; and amount of osteopontin in patient vs control plasma, measured using an enzyme-linked immunoassay.\nRESULTS: The geometric mean for 2(-DeltaDeltaCT)for osteopontin expression in 5 healthy ovarian epithelial cell cultures was 4.1 compared with 270.4 in 14 ovarian cancer cell lines (P =.03). The geometric mean 2(-DeltaDeltaCT)for osteopontin expression in tissue from 2 healthy ovarian epithelial samples was 9.0 compared with 164.0 in 27 microdissected ovarian tumor tissue samples (P =.06). Immunolocalization of osteopontin showed that tissue samples from 61 patients with invasive ovarian cancer and 29 patients with borderline ovarian tumors expressed higher levels of osteopontin than tissue samples from 6 patients with benign tumors and samples of healthy ovarian epithelium from 3 patients (P =.03). Osteopontin levels in plasma were significantly higher (P\u003c.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL).\nCONCLUSIONS: Our findings provide evidence for an association between levels of a biomarker, osteopontin, and ovarian cancer and suggest that future research assessing its clinical usefulness would be worthwhile."}